Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression.

Neurology·2025
Same author

Performance of <sup>123</sup>I-ioflupane SPECT striatal binding in dementia with Lewy bodies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy Bodies.

Neurology·2024
Same author

Metabolic and Environmental Biomarkers in Mild Cognitive Impairment and Dementia: An Exploratory Study.

Journal of integrative and complementary medicine·2024
Same author

ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2023
Same author

Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

Alzheimer's research & therapy·2020
Same journal

Glutamate-Glutamine metabolism and transport, implications in Parkinson's disease.

International review of neurobiology·2026
Same journal

Redox bioenergetics of neuronal senescence in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Neurovascular coupling and energy substrate delivery in Alzheimer's disease.

International review of neurobiology·2026
Same journal

From metals to mitochondria: Linking trace elements to energy crisis in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Invisible threats of microplastics induced toxicity: Oxidative and inflammatory pathways in the CNS and retina.

International review of neurobiology·2026
Same journal

Starved synapses: Gut microbiome dysbiosis and its role in Alzheimer's glucose impairment.

International review of neurobiology·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Lewy body dementia.

Jennifer C Hanson1, Carol F Lippa

  • 1Drexel University College of Medicine, Mail Stop 423, Philadelphia, Pennsylvania 19107, USA.

International Review of Neurobiology
|June 9, 2009
PubMed
Summary
This summary is machine-generated.

Dementia with Lewy bodies (DLB) is the second most common dementia, sharing features with Alzheimer's and Parkinson's disease. Understanding DLB's clinical, pathological, and radiological aspects is crucial for diagnosis and treatment.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 22, 2026

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Area of Science:

  • Neurology
  • Geriatrics
  • Pathology

Background:

  • Dementia prevalence is increasing due to longer lifespans and an aging population.
  • Alzheimer's disease (AD) is the most common dementia, followed by Dementia with Lewy bodies (DLB).
  • DLB presents with cognitive impairment, hallucinations, parkinsonism, and fluctuating confusion, often preceded by sleep disturbances.

Purpose of the Study:

  • To review Dementia with Lewy bodies (DLB).
  • To cover clinical, pathological, radiological features, biomarkers, and treatments for DLB.

Main Methods:

  • Review of clinical features of DLB.
  • Examination of pathological findings, including Lewy bodies (LB), alpha-synuclein, and ubiquitin.
  • Analysis of radiological features and biomarkers associated with DLB.

Main Results:

  • DLB shares pathological hallmarks (alpha-synuclein LB) with Parkinson's disease dementia (PDD).
  • DLB and PDD may represent a disease spectrum.
  • Co-occurrence of AD pathology (beta-amyloid, tau tangles) is frequent in DLB, influencing clinical presentation.

Conclusions:

  • DLB diagnosis requires careful consideration of overlapping features with AD and PDD.
  • Further research is needed to understand the overlap between DLB, PDD, and AD pathologies.
  • Comprehensive understanding of DLB's multifaceted nature is essential for effective patient management.